Q-linea (QLINEA) Q1 2025 earnings summary

Executive summary

• Q1 2025 saw record commercial progress, with five new customer contracts signed and the installed base expanding to at least seven systems in routine clinical use, surpassing all of 2024.

• Achieved a 20% year-over-year reduction in operating costs, with further production efficiencies planned.

• Strong momentum in both U.S. and international markets, including a master service agreement with a major U.S. reference lab and first tender wins in Benelux and Italy.

• Rights issue subscribed to 90.5%, raising SEK 204 million gross and SEK 93 million net new equity after repayments and costs.

• Continued positive reception at major industry conferences, with growing customer awareness and direct requests for evaluations.

Financial highlights

• Net sales reached SEK 3.7 million in Q1 2025, a 249–250% increase year-over-year, already exceeding the total for 2024.

• Operating costs reduced by 20% year-over-year, with monthly OPEX at SEK 13.9–15 million.

• Rights issue and directed share issue in March 2025 brought in SEK 204 million gross, SEK 93 million net after repayments and costs.

• Cash and cash equivalents at end of March 2025: SEK 68 million.

• Cost-saving program delivered SEK 4 million per month in savings, with additional SEK 10 million annual savings planned.

Outlook and guidance

• 2025 outlook remains strong with progress across clinical, commercial, and financial dimensions.

• Plan to maintain OpEx at SEK 14–15 million per month, with break-even targeted for 2027.

• Targeting 30–40 ASTar units contracted by end of 2025, with 60–90 planned for 2026.

• Anticipate increased recurring revenue from consumables as installed base grows.

• Gross margin expected to trend toward industry norms (60–80%) as scale increases, aiming for at least the midpoint by break-even in 2027.